Research Paper Volume 11, Issue 7 pp 2138—2150

MiR-204 reduces cisplatin resistance in non-small cell lung cancer through suppression of the caveolin-1/AKT/Bad pathway

Figure 7. miR-204 enhances the anti-tumor effect of cisplatin on cisplatin-resistant NSCLC in vivo. (A) Nude mice were inoculated with CR-A549/control or CR-A549/miR-204 cells before treatment with cisplatin (5 mg/kg) twice a week. Tumor volumes were detected every three days until the experimental end-point (28 days post-injection). (B) Expression of miR-204 in tumor tissues was measured by qRT-PCR analysis. *P<0.05 vs. CR-A549/control group. #P<0.05 vs. CR-A549/control+cisplatin group. (C) Expression of CAV-1 and phosphorylation of AKT and Bad were evaluated by western blot analysis.